Sandoz has announced the launch of generic oncology medicine lenalidomide, indicated for several haemato-oncology conditions as recommended by the latest European Society for Medical Oncology (ESMO) guidelines.
The medicine will become available to patients in 19 countries across Europe, the company said.
“We are proud to make life-enhancing cancer treatments more accessible by launching our affordable and effective Sandoz Lenalidomide”, said Rebecca Guntern, Head of Sandoz Europe.
She added: “Sandoz is committed to developing and providing generic oncology therapies, to increase patient access to affordable, high-quality medicines. Today, we offer a broad portfolio of more than 50 oncology products, ranging from biologics to chemotherapeutics, hormones and supportive care treatments, covering a wide range of cancer indications.”
The company noted that the cost of treating multiple myeloma patients is high and continues to rise. Affordability of and access to new multiple myeloma treatments pose a major challenge around the world6. Cost savings from Lenalidomide Sandoz promise to expand access to treatment options for multiple myeloma patients. Similar to multiple myeloma patients, cost savings from Lenalidomide Sandoz will benefit previously treated follicular lymphoma patients, adult patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality, and relapsed or refractory mantle cell lymphoma patients, the company said.